CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for
CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will
<i><b>-Registration program to evaluate improvements in lung function
(FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR
activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis
patients with the G551D mutation and to provide first evaluation of
activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement
in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>
<i>-Over 3 million Americans have chronic hepatitis C -</i>
-<i>Baby boomers account for 2 of every 3 cases of hepatitis C virus and
vast majority unaware they have this chronic disease </i>-
-<i>Cost burden of hepatitis C to Medicare projected to increase 500% as
baby boomers with HCV age into severe complications of liver disease-</i>
CAMBRIDGE, Mass., May 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2009 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan
CAMBRIDGE, Mass., May 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, 2009 at 8:40 a.m. EDT; at R. W.
CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of
<i><b>-Addition of telaprevir to standard HCV therapies significantly
improved rates of sustained viral response in half the time of current
treatments-</b></i><i><b>-SVR rates in Phase 2b studies of up to 69% with 24 weeks of
telaprevir-based treatment-</b></i><i><b>-Phase 3 program ongoing in more than 2,200 patients-</b></i>
<i>- Superior SVR rates with telaprevir across all HCV genotype 1
non-responders and relapser patients and patients with cirrhosis - up to
76% in prior relapsers -</i><i>- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens
compared to 14% in the 48-week control arm</i><i>-</i><i>- Treatment-failure patient population represents the greatest unmet
medical need in HCV -</i>
<i>-PROVE 3 results to be presented at late breaker session on Saturday,
April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate
activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid,
powerful antiviral activity with favorable safety and tolerability
profile-</i>